相似文献
1
Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists.
Bioorg Med Chem Lett. 2008 Sep 15;18(18):5111-4. doi: 10.1016/j.bmcl.2008.07.129. Epub 2008 Aug 7.
2
Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.
Eur J Med Chem. 2011 May;46(5):1841-8. doi: 10.1016/j.ejmech.2011.02.046. Epub 2011 Feb 23.
3
Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
Eur J Med Chem. 2021 Nov 15;224:113718. doi: 10.1016/j.ejmech.2021.113718. Epub 2021 Jul 24.
4
Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2.
Bioorg Med Chem Lett. 2009 Sep 1;19(17):5026-8. doi: 10.1016/j.bmcl.2009.07.048. Epub 2009 Jul 24.
5
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
CNS Spectr. 2018 Aug;23(4):239-247. doi: 10.1017/S1092852918001219.
6
Deuterated F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent.
Nucl Med Biol. 2018 Feb;57:42-49. doi: 10.1016/j.nucmedbio.2017.11.009. Epub 2017 Dec 6.
7
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Expert Rev Neurother. 2018 Apr;18(4):323-332. doi: 10.1080/14737175.2018.1455504. Epub 2018 Apr 2.
8
Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
J Endocrinol. 2008 Jul;198(1):41-9. doi: 10.1677/JOE-07-0632.
9
Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
Pharmacol Biochem Behav. 2020 Mar;190:172872. doi: 10.1016/j.pbb.2020.172872. Epub 2020 Feb 18.
10
Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands.
Bioorg Med Chem Lett. 2011 Jun 1;21(11):3435-8. doi: 10.1016/j.bmcl.2011.03.113. Epub 2011 Apr 5.
引用本文的文献
1
A role for foregut tyrosine metabolism in glucose tolerance.
Mol Metab. 2019 May;23:37-50. doi: 10.1016/j.molmet.2019.02.008. Epub 2019 Feb 27.
2
In vivo beta-cell imaging with VMAT 2 ligands--current state-of-the-art and future perspective.
Curr Pharm Des. 2010 May;16(14):1568-81. doi: 10.2174/138161210791164180.
3
Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.
Med Res Rev. 2011 Jul;31(4):483-519. doi: 10.1002/med.20187. Epub 2010 Feb 4.
本文引用的文献
1
Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
J Endocrinol. 2008 Jul;198(1):41-9. doi: 10.1677/JOE-07-0632.
2
Whole body [11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates.
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):790-7. doi: 10.1007/s00259-007-0648-2. Epub 2007 Dec 4.
3
1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.
Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70. doi: 10.1016/j.bmcl.2007.03.072. Epub 2007 Mar 25.
4
Vesicular monoamine transporter 2: role as a novel target for drug development.
AAPS J. 2006 Nov 10;8(4):E682-92. doi: 10.1208/aapsj080478.
5
Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.
J Clin Invest. 2006 Jun;116(6):1506-13. doi: 10.1172/JCI27645. Epub 2006 May 18.
6
Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors.
J Histochem Cytochem. 2003 Aug;51(8):1027-40. doi: 10.1177/002215540305100806.
7
Global and societal implications of the diabetes epidemic.
Nature. 2001 Dec 13;414(6865):782-7. doi: 10.1038/414782a.
8
Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding.
Mol Pharmacol. 1984 Jan;25(1):113-22.
Zotero 插件